Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 93 publications.

Weibel D, de Luise C, Cid Royo A, Ryan O, Vaz T, Aguado J, Marsal J, Garcia de Albeniz Martinez X, Weinrib R, Yefimenko N, Pala E, Poblador-Plou B, Gimeno-Miguel A, Santos-Mejias A, Marconi E, Barbieri E, Stona L, Lysen T, Roy D, Hyeraci G, Girardi A, Lupattelli A, Desalegn AA, Villalobos F, Bissacco CA, Kendrick K, Garg R, Rubino H, Sturkenboom MCJM, Arana A. Interim results from the VAC4EU Post-Authorization Safety Study (PASS) among recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) vaccine in Europe. Poster presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.

Garcia de Albeniz Martinez X, Aguado J, Caniglia E, Hernanez-Diaz S, Maringe C, Sterne J. Specification of time zero in causal inference studies using real-world data: challenges and solutions. Presented at the 2024 ISPE Annual Meeting; August 26, 2024. Berlin, Germany.

Aguado J, Gutierrez L, Forns J, Vila Guilera J, Rothman KJ, Garcia-Albeniz X. Effect of different durations of treatment with antihypertensive drugs with anticholinergic effects on the risk of dementia: a target trial emulation study. Am J Epidemiol. 2024 Aug 6. doi: 10.1093/aje/kwae263

Sung A, Houghton K, Cornely OA, Neofytos D, Pagliuca A, Capparella MR, Aguado J, Jimenez M, Gheorghe M. Effectiveness, safety, and patterns of real-world isavuconazole use—a retrospective medical record review study of patients with invasive aspergillosis. Poster presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023; April 15, 2023. Copenhagen, Denmark.

Chinthammit C, Mody R, Aguado J, Meyers J. Does weight loss in addition to HbA1c reduction impact health care costs in patients treated with T2D? a retrospective database analysis. Poster presented at the AMCP 2023 Annual Meeting; March 21, 2023. San Antonio, TX. [abstract] J Manag Care Pharm. 2023 Mar; 29(10-2):S27.

Aguado J, Gutierrez L, Rothman KJ, Garcia de Albeniz X. Effect of different durations of treatment with antihypertensive drugs with anticholinergic effects on the risk of dementia: a target trial emulation study. Presented at the 2022 ICPE Conference; August 27, 2022. Copenhagen, Denmark.

Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. Risk assessment of acute myocardial infarction and stroke associated with long-acting muscarinic antagonists, alone or in combination, versus long-acting beta2-agonists. Int J Chron Obstruct Pulmon Dis. 2022 Aug 2;17:1715-33. doi: 10.2147/COPD.S363997

Rebordosa C, Farkas DK, Montonen J, Laugesen K, Voss F, Aguado J, Bothner U, Rothman KJ, Zint K, Mines DI, Ehrenstein V. Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonists. Pharmacoepidemiol Drug Saf. 2022 Aug;31(8):827-39. doi: 10.1002/pds.5432

Saigi-Morgui N, Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud SZ, McMahon P, Perez-Gutthann S, Rivero-Ferrer E. Acute myocardial infarction, stroke, and MACE in COPD patients treated with aclidinium and other inhaled bronchodilators. Poster presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.

Forns J, Aguado J, Rivero-Ferrer E, Plana E, Dickerman BA, Garcia de Albeniz X. The effect of continuous use of antidepressants, with or without anticholinergic properties, for at least 4 months versus no treatment on the incidence of dementia: a target trial emulation. Poster presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.

Rivero-Ferrer E, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink S, Kristiansen NS, Hallas J, Pottegard A, Rebordosa C. Characteristics of new users of aclidinium bromide, aclidinium/formoterol, and other COPD medications in the United Kingdom, Denmark, and Germany. Clin Drug Invest. 2022 Apr;42(4):319-31. doi: 10.1007/s40261-022-01120-2

Forns J, Aguado J, Rivero-Ferrer E, Plana E, Dickerman B, Garcia de Albaniz X. The effect of the anticholinergic properties of antidepressants on the incidence of dementia: a target trial emulation. Presented at the Virtual ICPE 2021 Conference; August 23, 2021.

Rebordosa C, Plana E, Rubino A, Aguado J, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. A cohort study to evaluate the risk of hospitalisation for congestive heart failure associated with the use of aclidinium and other chronic obstructive pulmonary disease medications in the UK Clinical Practice Research Datalink. Int J Chron Obstruct Pulmon Dis. 2021 May 31;16:1461-75. doi: 10.2147/COPD.S301624

Rebordosa C, Rubino A, Witzleb AJ, Olesen M, Plana E, Aguado J, Saigi N, Daoud SZ, Lei A, Perez-Gutthann S, Schink T, Kristiansen NS, Pottegard A, Rivero-Ferrer E. Characteristics of new users of aclidinium, aclidinium/formoterol, and other COPD medications in three European countries. Poster presented at the 2020 Virtual ERS International Congress; October 2020. [abstract] Eur Respir J. 2020 Oct 28; 56(Suppl 64):2071. doi: 10.1183/13993003.congress-2020.2072

Martinez D, Ziemiecki R, Aguado J, Plana E, Rebordosa C. Is chronic obstructive pulmonary disease reco(r)ded similarly in CPRD GOLD and Aurum? Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Gutierrez L, Danysh HE, Aguado J, Hunt PR, Kaye JA, Garcia-Albeniz X, Gilsenan A. Value of adding secondary read diagnosis codes to identify breast cancer and bladder cancer in the Clinical Practice Research Datalink: a pilot validation study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Aguado J, Martinez D, Plana E, Ziemiecki R, Rebordosa C. Reco(r)ding of lifestyle variables in CPRD Aurum compared with GOLD. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Plana E, Ziemiecki R, Martinez D, Aguado J, Rebordosa C. Are diabetes and glucose-lowering drugs equivalently reco(r)ded in CPRD GOLD and Aurum? Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Danysh HE, Gilsenan A, Beachler DC, Kaye JA, Garcia-Albeniz X, Schmid R, Hunter S, Hunt PR, Aguado J, Calingaert B, Layton JB, Gutierrez L. Validation of breast cancer and bladder cancer among patients with type 2 diabetes mellitus in Medicare: a pilot study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Rivero-Ferrer E, Witzleb AJ, Olesen M, Plana E, Aguado J, Saigi-Morgui N, Rubino A, Daoud SZ, Lei A, Perez-Gutthann S, Schink T, Kristiansen NS, Pottegard A, Rebordosa C. Are aclidinium and aclidinium/formoterol used according to their approved indication in Europe? Results of a multicountry drug utilization postauthorization safety study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Rebordosa C, Houben E, Laugesen K, Bothner U, Montonen J, Aguado J, Overbeek JA, Ehrenstein V, Asmar J, Wallace L, Gilsenan AW. No evidence of off-label use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: a drug utilization study. Sci Rep. 2020 Jan 17;10(1):586. doi: 10.1038/s41598-019-57397-5

Rebordosa C, Houben E, Laugesen K, Asmar J, Montonen JT, Aguado J, Overbeek J, Ehrenstein V, Wallace L, Gilsenan A. Utilization of olodaterol and indacaterol in Europe. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):1128. doi: 10.1002/pds.4864

Plana E, Rivero-Ferrer E, Aguado J, Saigi-Morgui N, Nuevo J, Daoud SZ, Lei A, Perez-Gutthann S, Rebordosa C. Hospitalization for heart failure among patients using aclidinium bromide and other COPD medications: a post-authorisation safety study in the CPRD. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):1153. doi: 10.1002/pds.4864

Saigi N, Rebordosa C, Bui C, Aguado J, Plana E, Nuevo J, Daoud SZ, Lei A, Perez-Gutthann S, Rivero-Ferrer E. A validation exercise: identifying hospitalizations for heart failure among patients with COPD in the CPRD. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):334. doi: 10.1002/pds.4864

Rebordosa C, Aguado J, Plana E, Thomas S, Frances A, Lei A, Garcia-Gil E, Nuevo J, Perez-Gutthann S, Castellsague J. Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom. Respir Med. 2019 Jun;152:37-43. doi: 10.1016/j.rmed.2019.04.018

Pladevall-Vila M, Pottegard A, Schink T, Reutfors J, Morros R, Poblador-Plou B, Timmer A, Forns J, Hellfritzsch M, Reinders T, Hagg D, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Hallas J, Brandt L, Cortes J, Aguado J, Perlemuter G, Falissard B, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S. Risk of acute liver injury in agomelatine and other antidepressant users in four European countries: a cohort and nested case-control study using automated health data sources. CNS Drugs. 2019 Apr;33(4):383-95. doi: 10.1007/s40263-019-00611-9

Rebordosa C, Plana E, Aguado J, Thomas S, Garcia-Gil E, Perez-Gutthann S, Castellsague J. GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD). Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):126-33. doi: 10.1002/pds.4448

Rasouliyan L, Plana E, Martinez D, Aguado J, Ziemiecki R. The missing data problem: using propensity scores to estimate non-randomised treatment effects with missing covariate data. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.

Pladevall M, Pottegard A, Schink T, Reutfors J, Morros R, Poblador-Plou B, Timmer A, Forns J, Hellfritzsch M, Reinders T, Hagg D, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Hallas J, Kollhorst B, Brandt L, Cortes J, Aguado J, Perlemuter G, Falissard B, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S. Agomelatine and other antidepressants and the risk of acute liver injury (ALI), a post authorisation safety study (PASS) in four European countries. Poster presented at the 31st ECNP Congress; October 8, 2018. Barcelona, Spain. Previously presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

Pladevall M, Hallas J, Schink T, Reutfors J, Morros R, Poblador-Plou B, Forns J, Hellfritzsch M, Reinders T, Hagg D, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Pottegard A, Kollhorst B, Brandt L, Cortes J, Aguado J, Perlemuter G, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S. Agomelatine and other antidepressants and the risk of acute liver injury (ALI), a PASS in four European countries. Presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2018. Prague, Czech Republic. doi: 10.1002/pds.4629

Forns J, Cainzos-Achirica M, Hellfritzsch M, Giner-Soriano M, Poblador-Plou B, Hallas J, Morros R, Prados-Torres A, Pottegard A, Cortes J, Aguado J, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S, Pladevall M. How valid are the codes used to identify acute liver injury (ALI)? A study in 3 European data sources. Presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug 17; 27(S2):371-2. doi: 10.1002/pds.4629

Aguado J, Plana E, Saigi N, Garcia-Gil E, Castellsague J, Perez-Gutthann S, Rebordosa C. The missing puff: results of multiple imputation of ppFEV1 in CPRD. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):211-2. doi: 10.1002/pds.4629

Plana E, Rebordosa C, Aguado J, Saigi N, Garcia-Gill E, Castellsague J, Perez-Gutthann S. To pile or not to pile: how to define episodes of use of COPD medications in the CPRD. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):123. doi: 10.1002/pds.4629

Rivero-Ferrer E, Castellsague J, Aguado J, Plana E, Saigi N, Garcia-Gil E, Perez-Gutthann S, Rebordosa C. Are you really dead? Validation of death and date of death in patients with COPD in the CPRD. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):122-3. doi: 10.1002/pds.4629

Rebordosa C, Castellsague J, Aguado J, Thomas S, Plana E, García-Gil E, Lei A, Perez-Gutthann S. All-cause mortality in COPD patients treated with aclidinium and other inhaled bronchodilators. Poster presented at the 2018 American Thoracic Society (ATS) International Conference; May 21, 2018. San Diego, CA.

Pladevall M, Hallas J, Schink T, Morros R, Poblador-Plou B, Forns J, Hellfritzsch M, Reinders T, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Pottegard A, Kollhorst B, Cortes J, Aguado J, Perlemuter G, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S. Agomelatine and risk of hospitalization for acute liver injury: nested case-control study in Spain, Germany, and Denmark. Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 29, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):389. doi: 10.1002/pds

Rebordosa C, Castellsague J, Kristiansen N, Pottegard A, Plana E, Aguado J, Garcia-Gil E, Hallas J, Perez-Gutthann S. Severity of COPD in new users of aclidinium bromide and other COPD medications: a population-based study in the United Kingdom and Denmark. Presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):45-6. doi: 10.1002/pds

Plana E, Rebordosa C, Aguado J, Thomas S, Garcia-Gil E, Perez-Gutthann S, Castellsague J. Assessment of COPD severity in the UK CPRD. Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 30, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):576. doi: 10.1002/pds

Luciano JV, D’Amico F, Feliu-Soler A, McCracken LM, Aguado J, Penarrubia-Maria MT, Knapp M, Serrano-Blanco A, Garcia-Campayo J. Cost-utility of group acceptance and commitment therapy for fibromyalgia versus recommended drugs: an economic analysis alongside a 6-month randomized controlled trial conducted in Spain (EFFIGACT Study). J Pain. 2017 Jul;18(7):868-80. doi: 10.1016/j.jpain.2017.03.001

Novick D, Montgomery W, Treuer T, Koyanagi A, Aguado J, Kraemer A, Haro JM. Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder. Patient Prefer Adherence. 2017 Jun 6;11:1019-25. doi: 10.2147/PPA.S124581

Novick D, Montgomery W, Aguado J, Peng X, Haro JM. Factors associated with and impact of pain persistence in Asian patients with depression: a 3-month, prospective observational study. Int J Psychiatry Clin Pract. 2017 Mar;21(1):29-35. doi: 10.1080/13651501.2016.1242751

Rasouliyan L, Plana E, Aguado J. Considerations in the use of propensity scores in observational studies. Poster presented at the 2016 PhUSE Annual Conference; October 2016. Barcelona, Spain.

Farreny A, Aguado J, Corbera S, Ochoa S, Huerta-Ramos E, Usall J. Baseline predictors for success following strategy-based cognitive remediation group training in schizophrenia. J Nerv Ment Dis. 2016 Aug;204(8):585-9. doi: 10.1097/NMD.0000000000000509

Rebordosa C, Varas-Lorenzo C, Castellsague J, Plana E, Bui C, Aguado J, Garcia Gil E, Perez-Gutthann S. Characteristics of new users of aclidinium bromide in the United Kingdom. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):677. doi: 10.1002/pds.4070

Novick D, Montgomery W, Aguado J, Peng XM, Haro JM. Impact of anxiety symptoms on outcomes of depression: an observational study in Asian patients. Neuropsychiatr Dis Treat. 2016 Apr 11;12:795-800. doi: 10.2147/NDT.S90134

Novick D, Montgomery WS, Aguado J, Peng X, Brugnoli R, Haro JM. Which somatic symptoms are associated with an unfavorable course in Chinese patients with major depressive disorder? Asia Pac Psychiatry. 2015 Dec;7(4):427-35. doi: 10.1111/appy.12189

Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. BMC Psychiatry. 2015 Aug 5;15:189. doi: 10.1186/s12888-015-0560-4.

Rodríguez-Mías NL, Martínez-Franco E, Aguado J, Sánchez E, Amat-Tardiu L. Pelvic organ prolapse and stress urinary incontinence, do they share the same risk factors? Eur J Obstet Gynecol Reprod Biol. 2015 Jul;190:52-7. doi: 10.1016/j.ejogrb.2015.04.015

Aguado J, Luciano JV, Cebolla A, Serrano-Blanco A, Soler J, García-Campayo J. Bifactor analysis and construct validity of the Five Facet Mindfulness Questionnaire (FFMQ) in non-clinical Spanish samples. Front Psychol. 2015 Apr 9;6:404. doi: 10.3389/fpsyg.2015.00404

Hong J, Novick D, Montgomery W, Aguado J, Dueñas H, Peng X, Haro JM. Should unexplained painful physical symptoms be considered within the spectrum of depressive symptoms? Clin Pract Epidemiol Ment Health. 2015 Mar 31;11:130-9. doi: 10.2174/1745017901511010130